121 related articles for article (PubMed ID: 18687023)
21. Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009-2011: focus on clinical efficacy and safety.
Bushe CJ; Savill NC
J Psychopharmacol; 2014 Mar; 28(3):204-11. PubMed ID: 23438503
[TBL] [Abstract][Full Text] [Related]
22. Atomoxetine could improve intra-individual variability in drug-naïve adults with attention-deficit/hyperactivity disorder comparably with methylphenidate: A head-to-head randomized clinical trial.
Ni HC; Hwang Gu SL; Lin HY; Lin YJ; Yang LK; Huang HC; Gau SS
J Psychopharmacol; 2016 May; 30(5):459-67. PubMed ID: 26905919
[TBL] [Abstract][Full Text] [Related]
23. Switching from neurostimulant therapy to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder : clinical approaches and review of current available evidence.
Prasad S; Steer C
Paediatr Drugs; 2008; 10(1):39-47. PubMed ID: 18162007
[TBL] [Abstract][Full Text] [Related]
24. Atomoxetine. Attention-deficit/hyperactivity disorder: no better than methylphenidate.
Prescrire Int; 2010 Feb; 19(105):5-8. PubMed ID: 20455329
[TBL] [Abstract][Full Text] [Related]
25. Effects of atomoxetine and methylphenidate on sleep in children with ADHD.
Sangal RB; Owens J; Allen AJ; Sutton V; Schuh K; Kelsey D
Sleep; 2006 Dec; 29(12):1573-85. PubMed ID: 17252888
[TBL] [Abstract][Full Text] [Related]
26. ADHD update: new data on the risks of medication.
Harv Ment Health Lett; 2006 Oct; 23(4):3-5. PubMed ID: 17183739
[No Abstract] [Full Text] [Related]
27. A network meta-analysis of atomoxetine and osmotic release oral system methylphenidate in the treatment of attention-deficit/hyperactivity disorder in adult patients.
Bushe C; Day K; Reed V; Karlsdotter K; Berggren L; Pitcher A; Televantou F; Haynes V
J Psychopharmacol; 2016 May; 30(5):444-58. PubMed ID: 27005307
[TBL] [Abstract][Full Text] [Related]
28. Current pharmacotherapy of attention deficit hyperactivity disorder.
Reddy DS
Drugs Today (Barc); 2013 Oct; 49(10):647-65. PubMed ID: 24191257
[TBL] [Abstract][Full Text] [Related]
29. An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder.
Shang CY; Pan YL; Lin HY; Huang LW; Gau SS
J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):566-73. PubMed ID: 26222447
[TBL] [Abstract][Full Text] [Related]
30. A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom.
Cottrell S; Tilden D; Robinson P; Bae J; Arellano J; Edgell E; Aristides M; Boye KS
Value Health; 2008; 11(3):376-88. PubMed ID: 18489664
[TBL] [Abstract][Full Text] [Related]
31. Differential therapeutic effects of 12-week treatment of atomoxetine and methylphenidate on drug-naïve children with attention deficit/hyperactivity disorder: A counting Stroop functional MRI study.
Chou TL; Chia S; Shang CY; Gau SS
Eur Neuropsychopharmacol; 2015 Dec; 25(12):2300-10. PubMed ID: 26409297
[TBL] [Abstract][Full Text] [Related]
32. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial.
Wang Y; Zheng Y; Du Y; Song DH; Shin YJ; Cho SC; Kim BN; Ahn DH; Marquez-Caraveo ME; Gao H; Williams DW; Levine LR
Aust N Z J Psychiatry; 2007 Mar; 41(3):222-30. PubMed ID: 17464703
[TBL] [Abstract][Full Text] [Related]
33. Safety of attention-deficit/hyperactivity disorder medications in children: an intensive pharmacosurveillance monitoring study.
Ruggiero S; Rafaniello C; Bravaccio C; Grimaldi G; Granato R; Pascotto A; Sportiello L; Parretta E; Rinaldi B; Panei P; Rossi F; Capuano A
J Child Adolesc Psychopharmacol; 2012 Dec; 22(6):415-22. PubMed ID: 23234585
[TBL] [Abstract][Full Text] [Related]
34. Atomoxetine and stimulants in combination for treatment of attention deficit hyperactivity disorder: four case reports.
Brown TE
J Child Adolesc Psychopharmacol; 2004; 14(1):129-36. PubMed ID: 15142400
[TBL] [Abstract][Full Text] [Related]
35. New treatments and approaches for attention deficit hyperactivity disorder.
Newcorn JH
Curr Psychiatry Rep; 2001 Apr; 3(2):87-91. PubMed ID: 11276402
[No Abstract] [Full Text] [Related]
36. Review of ADHD pharmacotherapies: advantages, disadvantages, and clinical pearls.
Daughton JM; Kratochvil CJ
J Am Acad Child Adolesc Psychiatry; 2009 Mar; 48(3):240-248. PubMed ID: 19242289
[No Abstract] [Full Text] [Related]
37. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.
Gibson AP; Bettinger TL; Patel NC; Crismon ML
Ann Pharmacother; 2006 Jun; 40(6):1134-42. PubMed ID: 16735655
[TBL] [Abstract][Full Text] [Related]
38. Effects of stimulants and atomoxetine on cortisol levels in children with ADHD.
Isaksson J; Hogmark Å; Nilsson KW; Lindblad F
Psychiatry Res; 2013 Oct; 209(3):740-1. PubMed ID: 23850434
[TBL] [Abstract][Full Text] [Related]
39. What is the significance of the new warnings about suicide risk with Strattera?
Miller MC
Harv Ment Health Lett; 2005 Dec; 22(6):8. PubMed ID: 16437773
[No Abstract] [Full Text] [Related]
40. Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder.
Schulz KP; Fan J; Bédard AC; Clerkin SM; Ivanov I; Tang CY; Halperin JM; Newcorn JH
Arch Gen Psychiatry; 2012 Sep; 69(9):952-61. PubMed ID: 22945622
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
